年费超10万的老年痴呆症新药，首次进商保

Core Viewpoint - The release of China's first "Commercial Health Insurance Innovative Drug Directory" marks a significant turning point for Alzheimer's disease (AD) treatment, allowing for the inclusion of breakthrough drugs like Lecanemab and Donanemab, which previously had high treatment costs exceeding 100,000 yuan per year [1] Group 1: Drug Inclusion and Impact - Lecanemab and Donanemab are recognized as the most groundbreaking treatments for Alzheimer's disease, now included in the commercial insurance directory [1] - The inclusion of these drugs in the insurance directory represents the highest level of current treatment options available for Alzheimer's disease [1] Group 2: Market Transformation - The commercial insurance directory is expected to drive a profound transformation in the global Alzheimer's disease treatment market [1] - The number of Alzheimer's disease patients in China has surpassed 10 million, highlighting the urgent need for effective treatment options [1] Group 3: Historical Context - Historically, the clinical usage rate of Alzheimer's drugs has been low due to limited efficacy and high costs, creating a dilemma for many families [1] - The new policy aims to break this deadlock, providing hope for patients and their families [1]